ARV-393 is under clinical development by Arvinas and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase I drugs for Diffuse Large B-Cell Lymphoma have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ARV-393’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ARV-393 overview
ARV-393 is under development for the treatment of diffuse large B-Cell lymphoma, relapsed/refractory angioimmunoblastic T-cell lymphoma (AITL) and burkitt lymphoma. The drug candidate is administered through oral route as tablets. It acts by targeting B-cell lymphoma 6 (BCL6) and is being developed based on PROTAC (proteolysis-targeted chimera) technology.
Arvinas overview
Arvinas is a biopharmaceutical company that develops protein degradation therapeutics. The company develops novel therapeutics for the treatment of neuroscience, oncology, and other therapeutic areas. Its pipeline product includes oncology and immuno-oncology pipeline and Neuroscience pipeline. Oncology and immuno-oncology pipeline products include Vepdegestrant (ARV-471), Bavdegalutamide (ARV-110), ARV-766, ARV-393, AR-V7, HPK1 (I-O Program), KRAS-G12D/V, Myelocytomatosis (Myc) proteins. Neuroscience pipeline products include ARV-102, Alpha, Synuclein, mHTT, Tau. The company intends to expand its transformative protein degradation technology and its product candidates into clinical development through collaborations with pharmaceutical companies. Arnivas is headquartered in New Haven, Connecticut, the US.
For a complete picture of ARV-393’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
